{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057525","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.591560+00:00","generated_at":"2026-06-02T21:56:15.291408+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Annovis Bio CEO letter details Phase II/III AD data; will narrow enrollment to early-stage patients for next trial","bullets":["Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.","In moderate AD (MMSE 14-20), improvement was -0.65 vs placebo +1.79, indicating high placebo effect.","Next Phase III will prescreen for plasma AD biomarkers and enroll only early/mild AD (MMSE 21-28).","CEO states FDA will accept buntanetap for symptomatic relief and allow continuation for disease-modification study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057525","json":"https://secwatch.observer/filing/0001104659-24-057525.json","markdown":"https://secwatch.observer/filing/0001104659-24-057525.md","text":"https://secwatch.observer/filing/0001104659-24-057525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/0001104659-24-057525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/tm2413238d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:56:15.291408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}